Bpifrance

Leveraging cutting-edge quantum detectors, we design light, portable, and performing MRI machines working at ultra-low magnetic fields for a tenth of current prices.

Poppins merges music, technology, and neuroscience to reshape therapy into a musical experience. We create musical games for children based on neurologic music therapy methods. These games are designed to address learning dissabilities like dyslexia, providing a digital treatment at home and helping identify these conditions. Behind these games, we leverage data science and new technologies to interpret learning, language, and motor performance into a cognitive score. Our goal is to improve the process for patients receiving treatment and to reaching the vast undiagnosed majority.

H'ability offers therapeutic exercises in immersive virtual reality, complementary to conventional rehabilitation.

Parallel builds AI agents that streamline healthcare admin workflows, seamlessly integrated to unlock efficiency at scale.

Fizimed SAS, founded in 2017 and based in Strasbourg, France, specializes in manufacturing a perineal device designed to address urinary incontinence in women through pelvic floor reeducation. The company's flagship product, EMY, is a perineal probe that connects to a mobile app, allowing users to engage in personalized exercises for strengthening pelvic floor muscles. EMY not only captures real-time muscle contractions but also incorporates interactive elements, such as games, to motivate users during their five-minute workouts. Fizimed emphasizes user-friendliness and safety in its product design, aiming to empower women in managing their pelvic health at home. Additionally, the company actively seeks to eliminate the stigma surrounding urinary incontinence, fostering a supportive community on social media where women can share experiences and innovations related to this common health issue. Through its combination of medical efficacy and engaging technology, Fizimed aims to provide women with the tools they need to regain control over their pelvic health in a discreet and enjoyable manner.

MB Therapeutics is a pharmaceutical firm that provides patient-centric solutions for developing and producing tailored medicines.

EG 427 is a French biotechnology company that specializes in pinpoint gene therapy, aimed at treating disorders related to spinal cord injuries. The company utilizes HSV-1-based vectors, leveraging the natural characteristics of the Herpes Simplex Virus 1 to establish lifelong latency in peripheral neurons. This innovative approach allows for targeted and sustained expression of therapeutic genes, providing a potential cure for severe, chronic, and localized conditions, such as neurogenic bladder disorders resulting from spinal cord injuries. By focusing on this advanced gene therapy technique, EG 427 seeks to improve treatment outcomes for patients suffering from these debilitating conditions.

Ochy is a mobile application that leverages video technology and artificial intelligence to deliver lab-quality analysis of running techniques directly to users' smartphones. The platform is designed to help runners assess their biomechanics, identify weaknesses, and receive tailored exercise plans aimed at enhancing performance and preventing injuries. By analyzing users' movements, Ochy provides insights that can support athletes, coaches, and medical professionals alike. Coaches can utilize the app to better understand their athletes and optimize training programs, while runners without access to coaching can independently evaluate their technique. Additionally, medical professionals can use the application's analysis to assess patient techniques and guide rehabilitation efforts effectively.

Coave Therapeutics specializes in developing gene therapies aimed at treating rare ocular and central nervous system diseases. The company focuses on innovative solutions for rare retinal disorders, utilizing a recombinant adeno-associated virus that substitutes the viral DNA with a functional copy of the PDE6B gene. This therapeutic approach involves injecting the corrected version of the protein between the photoreceptors and the retinal pigment epithelium, providing patients with effective treatment options for various eye conditions.

Vetbiolix is a veterinary biotechnology company dedicated to developing innovative therapeutic solutions for dogs and cats. The company focuses on creating first-in-class drug candidates aimed at treating and preventing diseases that affect pets, particularly in areas such as periodontitis, osteoarthritis, and gut motility disorders. By emphasizing clinical development, Vetbiolix strives to offer effective treatments for common health issues in pets, ultimately enhancing their quality of life.

Orakl Oncology is dedicated to accelerating drug discovery in oncology using advanced biology and AI-powered analysis. The company utilizes a distinct collection of patient tumor avatars that integrates both biological and clinical data to enhance cancer treatment options.

Biolevate is an AI company specializing in the healthcare field. Their technology helps researchers and medical professionals by automating tasks like document generation and literature monitoring.

Theremia is an innovative health tech firm that uses cutting-edge AI technologies to revolutionize drug development. They specialize in neurological illnesses and optimize drug compounds for particular demographic groupings. Their technology offers more effective and individualized healthcare solutions, which increases treatment efficacy and decreases negative effects.

Doado is an e-health application that allows you to take care of your back problems.

Skezi is an e-cohort startup that believes that valuing the voices of patients, caregivers, families, and carers would enhance future health. SKEZI offers solutions adapted to all sectors of sensitive data through its subscription offer to its SaaS platforms.

Vaxinano is a biotechnology company focused on the preclinical and pharmaceutical development of vaccines and drug delivery systems for both humans and animals. Established in 2016, Vaxinano builds on 25 years of research and clinical trials related to vaccines, utilizing the patented technology of Pr Didier Betbeder. The company specializes in creating safe-by-design nanoparticles that adhere to green chemistry principles, which support the development of prophylactic and therapeutic vaccines for infectious diseases. Additionally, Vaxinano aids medical researchers in formulating drugs that activate biomolecules, proteins, and antigens, thereby facilitating innovative approaches to combat untreated viral, bacterial, and parasitic diseases.

Vetbiolix is a veterinary biotechnology company dedicated to developing innovative therapeutic solutions for dogs and cats. The company focuses on creating first-in-class drug candidates aimed at treating and preventing diseases that affect pets, particularly in areas such as periodontitis, osteoarthritis, and gut motility disorders. By emphasizing clinical development, Vetbiolix strives to offer effective treatments for common health issues in pets, ultimately enhancing their quality of life.

HEPTA Medical is a medical technology company focused on developing a microwave ablation platform for the treatment of early lung cancer. The company's innovative solution includes a microwave ablation catheter equipped with a proprietary temperature sensor, which allows healthcare professionals to monitor and control the ablation volume in real-time. This technology aims to provide a minimally invasive, nonsurgical treatment option, enhancing the efficiency and safety of cancer ablation procedures. By enabling precise control over the size of the lesion being treated, HEPTA Medical seeks to improve patient outcomes in cancer care.

Archeon is fully dedicated to the development of innovative solutions for the monitoring, diagnosis and treatment of critically ill patients in prehospital care.

UroMems is a company dedicated to addressing specific clinical needs related to patient care, particularly in the area of urology. It develops implantable medical devices aimed at enhancing existing surgical treatments, thereby improving patient outcomes and reducing side effects. By focusing on innovative solutions, UroMems seeks to ensure that more patients can access effective treatments quickly, ultimately aiming to enhance their quality of life. The company is committed to the design, development, and commercialization of these active implantable devices, which reflect a deep understanding of the challenges faced by patients.

Starkage Therapeutics is a discovery-stage biotechnology company focused on improving the quality of life for patients suffering from various health conditions. The company is developing a platform that targets the depletion of senescent cells, which are linked to age-related diseases, through a combination of immunotherapy and cancer treatment approaches. Starkage Therapeutics aims to address unmet medical needs in areas such as idiopathic pulmonary fibrosis, neurodegenerative diseases, and metabolic dysfunction or hepatic fibrosis. Through its innovative research and therapeutic strategies, the company seeks to enhance patient health and treatment outcomes.

Biodol Therapeutics, founded in 2015, develops first-in-class compounds for the treatment of chronic pain (CP). Biodol Therapeutics has identified the Receptor Tyrosine Kinase (RTK) FLT3 as a key player for triggering and maintaining the chronic neuropathic pain (NP) state. New findings from Biodol Therapeutics' academic partnership (Cyril Rivat and Jean Valmier at the INSERM Institute for Neurosciences in Montpellier) also demonstrated that FLT3 inhibition increases the potency of opioids for their analgesic effect, and hereby reduces their safety risks, especially addiction risk, which will help fighting the Opioid Crisis. The development of extracellular inhibitors of the FLT3 receptor, is a proprietary and key approach developed by Biodol Therapeutics.

Hephaistos Pharma is a biotechnology company focused on advancing oncology treatments through innovative immunotherapy solutions. The firm develops a platform that utilizes active and non-specific immuno-stimulants to enhance the effectiveness of existing antibodies by transforming cold tumors into hot targets, which can significantly improve patient outcomes. This approach aims to address unmet medical needs in cancer treatment, enabling patients to tackle previously incurable cancers. Hephaistos Pharma is dedicated to elevating immunotherapy efficiency by stimulating immune responses, thereby offering new hope in the fight against cancer. Interested parties can access more information through an online inquiry form available on the company's website.

May Health specializes in developing innovative solutions for infertility related to Polycystic Ovary Syndrome (PCOS). The company offers a minimally invasive procedure aimed at restoring ovulation in women with PCOS, providing a more natural approach to pregnancy. This one-time treatment is performed transvaginally under ultrasound guidance, eliminating the need for general anesthesia. The procedure is designed to assist the body's natural ovulation process and can be conducted in a clinical setting, similar to techniques used by fertility specialists in in vitro fertilization (IVF). May Health's focus is on delivering effective, durable solutions for patients seeking to conceive while minimizing the medicalization of the pregnancy experience.

Klineo is a platform that provides an intuitive and intelligent clinical trial search for oncology patients and doctors. The Klineo platform offers two interfaces for healthcare professionals and patients, allowing users to search for trials and contact centers.

Tribun Health specializes in developing diagnostic imaging software aimed at enhancing cancer detection and diagnosis. The company offers innovative solutions that facilitate the digital transformation of cancer diagnostics, enabling diagnostic laboratories and pharmaceutical and biotech businesses to manage, analyze, and share cellular images effectively. By providing advanced tools for digital microscopy-like image analysis and macroscopic imaging, Tribun Health ensures accurate diagnostics and scientific evaluations of patient cell and tissue images, contributing to improved healthcare outcomes in oncology.

SeaBeLife Biotech SAS is a biotechnology company based in Roscoff, France, established in 2019. The company focuses on developing innovative drug candidates aimed at treating acute pathologies, particularly acute liver and renal failure. SeaBeLife's products are derived from a family of patented molecules designed to block regulated necrosis, a type of regulated cell death. By targeting two synergistic pathways involved in various acute and chronic diseases, SeaBeLife aims to establish a new standard of care for patients with significant unmet medical needs. Through its research and development efforts, the company seeks to enhance patient outcomes and reduce complications associated with serious health conditions.

Leveraging cutting-edge quantum detectors, we design light, portable, and performing MRI machines working at ultra-low magnetic fields for a tenth of current prices.

ABIONYX Pharma SA is a biopharmaceutical company based in Labege, France, specializing in the discovery and development of high-density lipoprotein (HDL) therapies aimed at treating cardiovascular and metabolic diseases. The company is advancing a portfolio of HDL therapies, including CER-001, which is in Phase II clinical trials and is designed to mimic the properties of pre-beta HDL for patients with post-acute coronary syndrome and familial primary hypoalphalipoproteinemia. Additionally, ABIONYX is developing CER-209, a candidate in Phase I trials for metabolic diseases affecting the liver, as well as atherosclerosis and non-alcoholic steato-hepatitis. The company also focuses on innovative therapies for various conditions, including renal and ophthalmological diseases, and possesses a targeted drug delivery platform for oncology applications. Formerly known as Cerenis Therapeutics, ABIONYX Pharma rebranded in August 2019, continuing its commitment to addressing unmet medical needs.

HawkCell is a medical research company specializing in advanced magnetic resonance imaging (MRI) solutions for veterinary clinics and preclinical research laboratories. The company utilizes a non-ionizing three-dimensional (3D) imaging approach, employing specialized MRI sensors designed to accommodate various animal morphologies. By adapting human MRI technology for animal diagnostics, HawkCell provides sustainable systems enhanced with artificial intelligence algorithms. This innovation allows veterinary clinics and research labs to obtain precise and insightful imaging, facilitating improved animal healthcare and scientific exploration.

Pixee Medical is a medical technology company based in Chavanod, France, founded in 2017. The company specializes in the manufacturing of computer-assisted surgical solutions that utilize advanced computer vision and artificial intelligence technologies. Pixee Medical produces medical equipment designed to control the positioning of implants during orthopedic surgeries. Its innovative tracking tools enable precise three-dimensional localization of surgical objects, allowing healthcare professionals to perform procedures with millimeter accuracy. By focusing on affordability, Pixee Medical aims to provide effective surgical navigation solutions that address the challenges of the current healthcare environment.

I.Ceram SA, founded in 2005 and based in Limoges, France, specializes in the design, manufacture, and marketing of alumina bio-ceramic implants. The company produces implants for various joints of the human body, including the ankle, knee, hip, spine, shoulder, wrist, skull, tibia, and foot. In addition to joint implants, I.Ceram also offers osteosynthesis products. As a subsidiary of Investissement Développement, I.Ceram operates both domestically and internationally, focusing on high-tech solutions in the medical implant sector.

Ochy is a mobile application that leverages video technology and artificial intelligence to deliver lab-quality analysis of running techniques directly to users' smartphones. The platform is designed to help runners assess their biomechanics, identify weaknesses, and receive tailored exercise plans aimed at enhancing performance and preventing injuries. By analyzing users' movements, Ochy provides insights that can support athletes, coaches, and medical professionals alike. Coaches can utilize the app to better understand their athletes and optimize training programs, while runners without access to coaching can independently evaluate their technique. Additionally, medical professionals can use the application's analysis to assess patient techniques and guide rehabilitation efforts effectively.

Callyope is a human-centered technology that can enhance millions of people's lives by increasing the objectivity and responsiveness of brain health monitoring. Callyope develops solutions for remote patient monitoring that assist caregivers in identifying relapses and determining the best course of action.

Steto Its mission is to create solutions for remote patient monitoring and digital diabetes therapies.

Poppins merges music, technology, and neuroscience to reshape therapy into a musical experience. We create musical games for children based on neurologic music therapy methods. These games are designed to address learning dissabilities like dyslexia, providing a digital treatment at home and helping identify these conditions. Behind these games, we leverage data science and new technologies to interpret learning, language, and motor performance into a cognitive score. Our goal is to improve the process for patients receiving treatment and to reaching the vast undiagnosed majority.

EverImmune is focused on developing innovative biotherapeutic products aimed at treating cancer patients through microbiome oncology. The company specializes in creating live biotherapeutic products (LBP) that serve as oral adjuvants to enhance anticancer immunotherapies. By leveraging technology to safely boost the immune system and restore sensitivity to immunotherapies, EverImmune seeks to improve the effectiveness of cancer treatments, particularly in cases of primary resistance. The firm plans to conduct well-designed clinical trials to test its lead product, Oncobax®, as part of its commitment to advancing cancer care.

Tribun Health specializes in developing diagnostic imaging software aimed at enhancing cancer detection and diagnosis. The company offers innovative solutions that facilitate the digital transformation of cancer diagnostics, enabling diagnostic laboratories and pharmaceutical and biotech businesses to manage, analyze, and share cellular images effectively. By providing advanced tools for digital microscopy-like image analysis and macroscopic imaging, Tribun Health ensures accurate diagnostics and scientific evaluations of patient cell and tissue images, contributing to improved healthcare outcomes in oncology.

Teale is a digital mental health platform that integrates psychology and technology to enhance mental well-being. The platform offers personalized and interactive digital healthcare solutions, enabling individuals to manage their mental health effectively. Teale also conducts collective workshops tailored to specific needs within workplaces, fostering a supportive environment for mental health initiatives. Through its curated network of mental health experts, Teale provides individual support and personalized digital programs, allowing users to monitor and improve their psychological resilience. This approach not only benefits individuals but also contributes to sustainable growth for organizations.

Pollen Robotics designs and develops humanoid service robots that cater to the healthcare, retail, and education sectors. These robots are equipped with advanced robotic arms that enable precise object manipulation, facilitating various tasks. Pollen Robotics emphasizes customization and connectivity in its products, allowing users to adapt the robots for different applications. The technology also incorporates features to convey emotions, which enhances interaction and engagement. This innovative approach allows scientists, artists, and innovators to explore new possibilities, making the potential of robotics accessible to a broader audience.

X-Pressure is a medical device to measure cerebrospinal fluid pressure to better diagnose brain diseases.

Gleamer develops artificial intelligence solutions tailored for radiology, focusing on enhancing diagnostic accuracy and efficiency in medical imaging. The company's AI Companions integrate seamlessly into the existing workflow of radiologists, providing automated second readings that assist in detecting and highlighting bone abnormalities on X-ray images. This technology enables the early identification of lesions and prioritization of patient care, helping to ensure that diagnoses are made promptly and accurately. Currently, Gleamer's solutions are utilized in over 300 institutions across 13 countries, reflecting the widespread adoption of its advanced diagnostic tools in the healthcare sector.

Numa Health is a medical bioinformatics company that develops a digital health platform aimed at helping individuals optimize their health and well-being. The platform offers tools that reinterpret blood test results, providing users with insights into their body's functioning. By delivering accessible health information, Numa Health enables individuals to measure, understand, and take action regarding their health, fostering a greater commitment to personal health management.

CorWave is a developer of advanced implanted cardiac support devices aimed at improving the quality of life for patients with heart failure. The company's flagship product, an innovative left ventricular assist device (LVAD), employs a unique undulating disc wave pumping mechanism. This design enhances blood flow by mimicking the natural pulsation of the heart, significantly reducing trauma to blood and minimizing complications associated with clotting and bleeding, which are common with traditional continuous flow pumps. Additionally, CorWave's LVAD is characterized by low power consumption and compact size, making it suitable for complete implantation and integration with a wireless energy transfer system. Through its pioneering technology, CorWave seeks to alleviate the burdens of heart failure and lessen the need for invasive surgical interventions.

Santexpat is a health insurance platform for French expatriates in more than 200 countries. It allows users to analyze more than 100 health insurance solutions and subscribe to them directly. The company also offers teleconsultations with French-speaking doctors 24/7. Santexpat was founded in 2020 and is based in Paris, France.

IA Medical transforms raw data into intelligent patient knowledge. Its algorithms help to understand patient data, from diagnosis to follow-up, to support them with its conversational agents but also to set up a hybrid solution of cognitive and behavioral therapies.

Kairos Discovery is a biotechnology company focused on developing innovative targeted cancer therapies. The company aims to create medicinal chemistry solutions that address key cellular mechanisms responsible for the survival and aggressiveness of both solid tumors and hematological cancers. By utilizing a first-in-class approach, Kairos Discovery seeks to provide breakthrough technology in oncology, ultimately improving the lives of cancer patients and their families.

Maddie provides patient and practice management software solutions for physiotherapists.

Santé Académie is an online training platform focused on providing continuous medical education to healthcare professionals. Recognizing the evolving roles of caregivers and the rapid obsolescence of medical knowledge, the platform offers high-quality educational videos tailored to the schedules of busy professionals. Each course is divided into short episodes ranging from 5 to 15 minutes, allowing doctors, nurses, pharmacists, and care assistants to learn at their own pace. The courses cover clinical and regulatory topics and are certified by the ANDPC, produced by experts from prestigious institutions. With the aim of enhancing patient care and engagement, Santé Académie has already gained approval from over 20,000 professionals and health institutions, making advanced medical knowledge accessible directly from mobile devices.

Odimma is a biotech company that focuses on precision medicine and cure for personalized cancer immunotherapy.

Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, focused on developing innovative therapies for advanced liver diseases, including liver fibrosis, cirrhosis, and liver cancer. Established in 2019, Alentis is recognized for its pioneering work in targeting CLDN1+ cancers through the use of anti-CLDN1 antibody-drug conjugates and other therapeutic modalities. The company's research platform incorporates clinically relevant read-outs and single-cell RNA sequencing of patient liver tissues, which aids in understanding and treating fibrotic diseases. Alentis aims to modify and reverse disease progression, ultimately addressing significant health challenges associated with liver-related conditions.

Hemerion is a biotechnology company dedicated to developing innovative cancer treatments, specifically targeting glioblastoma, the most prevalent and aggressive primary brain tumor. The company operates a platform that integrates therapeutic services at the intersection of surgery and photonics, utilizing a photosensitizing drug for a drug-device combination therapy. This approach enables healthcare professionals to selectively destroy cancer cells in regions that are difficult to access through traditional surgical methods, all while preserving healthy tissues. Hemerion's focus on advanced treatment options aims to enhance the healthcare industry's ability to combat brain cancer and improve patient outcomes in the fight against glioblastoma.

Kayentis is a global leader in electronic clinical outcome assessment (eCOA) and decentralized clinical trial solutions, dedicated to enhancing data collection processes in clinical trials for the pharmaceutical, biotech, and contract research organization sectors. Founded in 2005, the company has developed expertise in eCOA solutions applicable across all phases of clinical development, addressing over 200 indications in more than 20 therapeutic areas. To meet the evolving demands of clinical research, Kayentis offers a comprehensive suite of services that prioritize scientific integrity and patient-centric approaches. With operational capabilities spanning the USA, Europe, and Asia, the company's technology facilitates electronic data capture, providing a versatile range of tools designed to simplify data collection for both patients and clinical trial sites.

Orthopus manufactures and distributes medical devices. They develop a range of robotic devices for arm mobility. Their supporter compensates for the weight of the arm to facilitate vertical movements. Their robotic device is used in an electric wheelchair and on a table.

WeLinQ is an online platform that provides free consultation services and easy messaging with therapists. They provide a practical substitute for in-person therapy with advantages including anytime messaging, adaptable scheduling, simple therapist switching, and the capacity to take part in sessions from any location.

Elis is a multi-services group operating in Europe and Brazil, specializing in the rental and maintenance of professional clothing, flat linen, and hygiene appliances. The company provides a wide range of tailored solutions, including services for washrooms, floor protection, beverages, cleanrooms, pest control, and medical waste management. With over 19,000 employees across 13 countries, Elis serves more than 240,000 businesses in various sectors, including hospitality, healthcare, industry, retail, and services. The company's extensive network of nearly 300 production and distribution centers, alongside 13 clean rooms, enables it to maintain strong proximity to its clients and deliver high-quality services efficiently. With over a century of experience, Elis has established itself as a leader in cleanliness, image, hygiene, and well-being services.

Ganymed Robotics SAS is a medical device company based in Paris, France, established in 2018. The company specializes in developing advanced robotics technologies and software aimed at enhancing surgical precision in orthopedic procedures, particularly focusing on knee replacement surgeries. Its innovative therapeutic device is designed to improve patient outcomes and streamline the surgical process, enabling orthopedic surgeons to reduce operating times and enhance their overall experience. By integrating robotics into surgical practices, Ganymed Robotics aims to advance the efficiency of care delivery in the orthopedic field.

Clarity is a clinical-stage company pioneering a new category of non-pharmacological treatments for neurodegenerative diseases. We develop a neuromodulation device combining immersive technology, AI and biosensors to deliver gamma sensory stimulation. Gamma waves’ sensory stimulation has been shown to significantly slow down Alzheimer's progression, reducing neurodegeneration and cognitive decline. Clarity takes a platform approach by enabling the customization of sensory stimulation protocols based on patient data, improving experience, efficacy and scalability across a wide range of indications. The company was founded by neuroscientists from UC Berkeley, and Oxford along with execs from OURA and Philips, and is supported by leading institutions such as UCSF's Neuroscape.

Microphyt specializes in the research, development, production, and marketing of natural algae-based products aimed at enhancing health and wellness. The company focuses on creating bioactive dietary supplements that support weight loss and brain health. Utilizing an industrial-scale supply of microalgae biomass and extracts, Microphyt ensures the preservation of cell integrity while producing commercial quantities of slow-growing or biofilm-forming species. This approach enables the healthcare industry to effectively meet the demands of personal care and food products, positioning Microphyt as a key player in the market for natural health solutions.

Meccellis Biotech SAS, founded in 2013 and based in La Rochelle, France, specializes in developing biologic implants using acellular dermis. The company focuses on tissue and cell engineering to create biological implants that facilitate tissue repair across various surgical specialties. Their product offerings include Cellis and Cellis breast implants, designed to address specific clinical needs during surgical procedures, such as abdominal wall repair. By maintaining continuous communication with surgeons, Meccellis Biotech aims to provide tailored solutions that meet the evolving demands of the medical field.

Jalon Therapeutics is focused on developing innovative therapies that target essential tumor signaling pathways that have not yet been addressed. The company aims to transform the lives of cancer patients by creating medicines that effectively inhibit these pathways. Through its research, Jalon Therapeutics explores the potential of non-oncogene addiction to discover new therapeutic targets and develop groundbreaking anticancer treatment strategies. The company's work is centered on improving treatment options for individuals battling cancer, ultimately striving to enhance their quality of life.

Lys Therapeutics is a biotechnology company focused on developing therapies for patients with neurovascular and neurodegenerative disorders. The company is centered around its lead product, Glunozumab, a monoclonal antibody that operates through a unique mechanism of action. This drug induces off-target toxicity by hyperactivating vascular and neuronal NMDA receptors, which can lead to significant disruptions in the blood-brain and blood-spinal cord barriers, as well as neuronal excitotoxicity. These effects are particularly relevant in conditions such as stroke and multiple sclerosis, where the modulation of neuroinflammation is critical for treatment.

Incepto is a developer of an artificial intelligence-based medical imaging platform aimed at addressing the challenges faced by healthcare professionals overwhelmed by patient volume and medical images. The platform offers advanced tools for interpreting computed tomography scans, chest x-rays, and detecting conditions such as fractures and bowel occlusions. Incepto specializes in creating AI-driven applications for mammogram screening and automated management of pulmonary nodules, facilitating enhanced patient care. The company's mission is to empower healthcare professionals by involving them in the AI production process through co-creation projects, ensuring that the tools developed meet the real needs of physicians and data scientists.

SparingVision is a biotechnology company focused on the discovery and development of innovative therapies for the treatment of blinding inherited retinal diseases. SparingVision is developing SPVN06, a gene-independent treatment for retinitis pigmentosa, the most common inherited retinal degeneration. There is currently no treatment to treat all genetic forms of this rare retinal disease that leads to blindness and affects nearly 2 million people worldwide.

Cuure specializes in providing personalized vitamins and supplements tailored to individual health requirements. Utilizing data from health questionnaires and DNA tests, Cuure develops customized supplement plans aimed at enhancing overall health and wellness. Their offerings combine scientific research with a personalized approach, ensuring that users receive recommendations aligned with their specific health goals and body chemistry. Additionally, the platform promotes wellness habits through a tracking application, allowing individuals to monitor their supplement intake and adapt their health practices effectively. Cuure's commitment to fair pricing and personalized solutions makes it a distinctive player in the wellness industry.

Leveraging cutting-edge quantum detectors, we design light, portable, and performing MRI machines working at ultra-low magnetic fields for a tenth of current prices.

Qairn specializes in digitizing regulatory processes for healthcare manufacturers, including laboratories, medical devices, and biotechs. The company offers a SaaS platform that streamlines and secures mandatory procedures, facilitating the management of promotional materials and other regulated content. Qairn's services include the review and validation of promotional documents, submission to ANSM, and compliance support, allowing clients to efficiently navigate regulatory requirements while minimizing risks. By simplifying these processes, Qairn enables its clients to focus on innovation and improving healthcare outcomes.

SPART supports companies in the process of improving quality of life at work by offering solutions to activate health and well-being practices each day in a professional environment. They are partners for corporate sporting challenges. They enable everyone to achieve their full potential through innovative physical activities within the company.

Ludocare is to create ways to provide assistance to patients and their families to improve their abilities, autonomy, and quality of life.

Sonio is an AI-based support platform for fetal ultrasound, helping practitioners analyze and diagnose congenital malformations. Sonio combines the patient’s medical history, genetic and biological data, and ultrasound semiology to assist physicians on the path to the right diagnosis. It assists sonographers during prenatal screening scans, helping them ensure that they have not forgotten anything, take risk factors into account, and facilitate the sharing of images with patients and other health professionals.

Nurea develops a decision-making support solution specifically for healthcare professionals, particularly vascular surgeons. The company specializes in medical imaging software that automates image analysis, providing accurate quantitative assessments to aid in the diagnosis of vascular diseases. Its platform facilitates the management of patient groups during both pre- and post-operative monitoring through an automated workflow, which includes comprehensive full-body scan analysis. By offering decision indicators aimed at preventing cardiovascular incidents, Nurea simplifies the decision-making process for surgeons, enhancing patient care in the realm of cardiovascular health. An online inquiry form is available on their website for further information.

Healshape is a biotech startup dedicated to developing natural breast reconstruction solutions for women. The company specializes in regenerative medicine, focusing on creating innovative alternatives for breast regeneration through advanced 3D bioprinting technology. Healshape's primary product is a bioprosthesis designed for breast reconstruction, which aims to empower women by helping them regain self-confidence and achieve long-lasting, aesthetically pleasing results following surgery.

Implicity is a developer of a remote monitoring platform that specializes in the smart monitoring of patients with connected cardiac devices, such as pacemakers and defibrillators. The platform utilizes artificial intelligence to sort and summarize patient data, assessing the criticality of alerts based on individual medical contexts. This capability allows cardiologists and healthcare professionals to automate the monitoring process, enabling them to effectively oversee patient health while consolidating information on a single platform. By streamlining remote monitoring, Implicity aims to enhance the quality of care provided to patients with cardiac implants.

Hemerion is a biotechnology company dedicated to developing innovative cancer treatments, specifically targeting glioblastoma, the most prevalent and aggressive primary brain tumor. The company operates a platform that integrates therapeutic services at the intersection of surgery and photonics, utilizing a photosensitizing drug for a drug-device combination therapy. This approach enables healthcare professionals to selectively destroy cancer cells in regions that are difficult to access through traditional surgical methods, all while preserving healthy tissues. Hemerion's focus on advanced treatment options aims to enhance the healthcare industry's ability to combat brain cancer and improve patient outcomes in the fight against glioblastoma.

Ribonexus is a biotechnology company dedicated to developing innovative therapies aimed at treating cancer, particularly melanoma. The company is focused on creating a pipeline of small molecules that target the eukaryotic translation Initiation Factor-4A (eIF4A), which plays a significant role in various solid and hematologic cancers. This target is particularly relevant for addressing resistance to existing treatments, which often diminishes the effectiveness of targeted therapies. Ribonexus aims to produce drugs that can restore sensitivity to these therapies in patients who have developed resistance, thereby improving treatment outcomes in oncology.

Ribonexus is a biotechnology company dedicated to developing innovative therapies aimed at treating cancer, particularly melanoma. The company is focused on creating a pipeline of small molecules that target the eukaryotic translation Initiation Factor-4A (eIF4A), which plays a significant role in various solid and hematologic cancers. This target is particularly relevant for addressing resistance to existing treatments, which often diminishes the effectiveness of targeted therapies. Ribonexus aims to produce drugs that can restore sensitivity to these therapies in patients who have developed resistance, thereby improving treatment outcomes in oncology.

LimFlow System is approved for sale in markets regulated by the CE Mark. Investigational device in the United States. Limited by U.S. federal law to investigational use only in the U.S. LimFlow is a game-changing technology that enables clinicians to bring new hope to end-stage chronic limb ischemia (CLI) patients, when all other revascularization efforts have been exhausted. By restoring perfusion to the ischemic foot through a completely novel, percutaneous procedure, the LimFlow System can relieve ischemic pain, promote wound healing, reduce amputations and restore mobility for patients when used as part of a multi-disciplinary team approach.

Cairdac is a medtech startup focused on developing an innovative leadless pacing system that utilizes a self-sustaining power technology. The company has achieved a significant milestone by creating the first self-sustaining pacemaker with a lifespan exceeding 15 years, leveraging a proprietary piezoelectric energy harvester in conjunction with a miniaturized power management circuit. Their unique product, the ALPS, is an autonomous and endoscopically implanted leadless pacemaker designed to harness the heart's kinetic energy for power. By integrating disruptive technologies into traditional pacemaker designs, Cairdac aims to provide a cost-effective solution that addresses the evolving needs of patients and healthcare professionals while enhancing the overall quality of life for those requiring cardiac rhythm management.

Vaxxel is an Innovative viral live-attenuated platform that develops novel and proprietary live-attenuated vaccine candidates against bronchiolitis and pneumonia caused by pneumovirus.

Archeon is fully dedicated to the development of innovative solutions for the monitoring, diagnosis and treatment of critically ill patients in prehospital care.

Doctolib is an online healthcare booking platform and management software provider based in Paris, France, founded in 2013. The company offers a comprehensive service for healthcare practitioners, enabling them to manage appointments, reduce no-shows, and attract new patients. For patients, Doctolib provides a free and user-friendly online service that allows individuals to easily find local health practitioners and book appointments for medical or dental consultations at any time. By streamlining the appointment process, Doctolib enhances access to healthcare services for both professionals and patients, facilitating better management of consultations and patient interactions.

SeaBeLife Biotech SAS is a biotechnology company based in Roscoff, France, established in 2019. The company focuses on developing innovative drug candidates aimed at treating acute pathologies, particularly acute liver and renal failure. SeaBeLife's products are derived from a family of patented molecules designed to block regulated necrosis, a type of regulated cell death. By targeting two synergistic pathways involved in various acute and chronic diseases, SeaBeLife aims to establish a new standard of care for patients with significant unmet medical needs. Through its research and development efforts, the company seeks to enhance patient outcomes and reduce complications associated with serious health conditions.

Cell-Easy SAS is a contract development and manufacturing organization based in Toulouse, France, specializing in stem cell services for preclinical and clinical drug development. Founded in 2017, the company focuses on providing ready-to-inject adipose-derived allogeneic stem cells, utilizing biological material from healthy donors. This approach enables the healthcare industry to reduce manufacturing costs associated with stem cell therapies, addressing affordability challenges in the field. By streamlining access to these stem cells, Cell-Easy supports various development projects aimed at improving patient outcomes.

NaoX Technologies is focused on preventing neurological disorders through innovative connected solutions. The company has developed wireless headphones equipped with integrated sensors that passively monitor brain activity by detecting brain vibrations. These headphones record electroencephalogram data in real time and aggregate the information on a software dashboard for healthcare professionals. By providing this technology, NaoX Technologies aims to democratize access to neurological disorder prevention and support patients in their recovery from mental health issues.

VistaCare is a French company specializing in the development, manufacturing, and distribution of medical devices designed for the treatment of acute and chronic wounds. The company focuses on innovative, non-contact treatment methods that operate in a controlled environment. Their technology addresses critical aspects of wound care, including the reduction of nosocomial risks, visual monitoring of wound progression, and tailored medical protocols based on the specific type and stage of each wound. By enhancing the quality of life for patients and streamlining the care process for caregivers, VistaCare aims to significantly reduce treatment times and hospital stays, offering a more effective solution for complex wounds that are challenging to manage with conventional therapies.

Starkage Therapeutics is a discovery-stage biotechnology company focused on improving the quality of life for patients suffering from various health conditions. The company is developing a platform that targets the depletion of senescent cells, which are linked to age-related diseases, through a combination of immunotherapy and cancer treatment approaches. Starkage Therapeutics aims to address unmet medical needs in areas such as idiopathic pulmonary fibrosis, neurodegenerative diseases, and metabolic dysfunction or hepatic fibrosis. Through its innovative research and therapeutic strategies, the company seeks to enhance patient health and treatment outcomes.

Heroic Sante is a virtual platform. They offer patients the chance to have their questions answered by qualified carers and learn from other patients. Their community works to create useful projects for patients and finances them thanks to statements on applications.

Fysali breaks the taboo by providing remote, non-invasive bladder monitoring. They offer superior clinical accuracy, an exceptional patient experience, and a lower cost of care. They offer remote and noninvasive bladder monitoring services.

Hypno VR SAS is a company that specializes in developing and operating virtual reality-based medical hypnosis solutions aimed at managing pain and stress. Founded in 2016 and headquartered in Strasbourg, France, Hypno VR creates applications designed to facilitate medical hypnosis during procedures, thereby reducing anxiety and discomfort for patients. The company's technology is particularly beneficial in various medical fields, including pediatric surgery, gastroenterology, gynecology, and dental surgery. In addition to its software solutions, Hypno VR also develops virtual reality hardware tailored for medical applications, catering to health professionals and institutions seeking innovative ways to enhance patient care.

Lysogene is a pioneer in the basic research and clinical development of gene therapy for neurodegenerative disorders . Their mission is to radically improve the health of patients suffering from incurable life threatening conditions. They do this by developing AAV vectors that have demonstrated their effectiveness in safely delivering genetic material to the central nervous system.

Egle Therapeutics SAS is a biotechnology company based in Paris, France, founded in 2020. It specializes in developing innovative immunotherapies that target immune suppressor regulatory T-cells (Tregs) for the treatment of oncology and autoimmune diseases. The company's research focuses on a proprietary drug pipeline that includes computationally designed IL-2 variants aimed at modulating Treg activity. This approach seeks to either engage or dis-engage Tregs, facilitating the development of therapies that can effectively combat cancer and other related conditions by addressing the immune suppression caused by Tregs. Egle Therapeutics aims to advance its unique portfolio to provide new treatment options in the healthcare field.

TreeFrog Therapeutics is a developer of stem cells intended to secure cell production and quality, fasten clinical development and facilitate market access. The company's offerings include a proprietary technology platform that provides an end to end 3D scalable solution that will dramatically reduce treatment costs, enabling patients to access the medical revolution of cell therapies by overcoming current critical manufacturing issues.

PEP-Therapy is a biotechnology company focused on developing innovative peptide-based therapies aimed at treating severe diseases, particularly cancer. The company specializes in creating Cell Penetrating and Interfering Peptides (CP&IP), which are designed to penetrate cellular membranes and effectively block critical intracellular protein-protein interactions. By doing so, these peptides aim to inhibit essential pathological mechanisms, thereby offering targeted therapeutic options for healthcare providers. Through its research and development efforts, PEP-Therapy seeks to advance the field of targeted therapies and improve outcomes for patients facing serious health challenges.

Alkion BioInnovations, established in March 2017, focuses on developing innovative cannabinoid and pharmaceutical active pharmaceutical ingredient (API) production through large-scale plant tissue culture. The company utilizes proprietary semi-industrial technologies to produce natural plant active ingredients for pharmaceutical applications, aiming to create disruptive nutrition, non-cosmetic oil, and agrochemical products for both the pharmaceutical and agri-food sectors. In addition to its work in cannabinoid production, Alkion is also developing a novel plant-based high-intensity protein sweetener as a sugar replacement. The company has received multiple R&D grants and awards, including those from I-lab, I-Nov, and the European Innovation Council, recognizing its contributions to biotechnology and innovation.

Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, focused on developing innovative therapies for advanced liver diseases, including liver fibrosis, cirrhosis, and liver cancer. Established in 2019, Alentis is recognized for its pioneering work in targeting CLDN1+ cancers through the use of anti-CLDN1 antibody-drug conjugates and other therapeutic modalities. The company's research platform incorporates clinically relevant read-outs and single-cell RNA sequencing of patient liver tissues, which aids in understanding and treating fibrotic diseases. Alentis aims to modify and reverse disease progression, ultimately addressing significant health challenges associated with liver-related conditions.

Omnidoc is a tele-expertise platform focused on enhancing communication among healthcare professionals. It enables the exchange of medical opinions by facilitating phone-based medical verification for patients who qualify for health insurance. The platform serves medical institutions and private physicians by streamlining the process of obtaining informal medical opinions, strengthening connections between primary and specialized care providers, and centralizing requests from correspondents. Additionally, it allows users to identify and connect with doctors and healthcare organizations, thereby improving the quality and security of the opinions exchanged. Omnidoc also automates several administrative tasks, contributing to a more efficient healthcare experience for both providers and patients.

Arkhn is a company focused on healthcare data interoperability, addressing challenges related to accessing and managing healthcare data. It develops medical enterprise software that standardizes healthcare information to enhance patient care and support medical teams. By improving data accessibility, Arkhn aims to facilitate medical research and innovation while streamlining the operations of healthcare centers. This enables healthcare establishments to provide better support for patients and caregivers, ultimately accelerating advancements in the healthcare sector.

Victor Pauchet offers maternity and obstetrics services. Their medical care services include angiology, cardiology, dermatology, endocrinology, geriatrics, gynecology, medicine, sports, neurology, nephrology, osteopathy, pediatrics, pulmonology, palliative care, and urology. Surgical services include centers for ophthalmology, bariatric, digestive, plastic, reconstructive, breast, thoracic, urological, vascular, ENT surgery, maxillofacial, stomatology, neurosurgery, spine, traumatology, and orthopedics services.

Pixyl is a developer of a neuroimaging cloud platform that enhances patient care for radiologists by providing critical decision-making information from neuroimaging data. Their platform, Pixyl.Neuro, utilizes advanced machine learning techniques to automatically analyze MRI images, offering detailed insights into brain structures such as grey matter, white matter, and intracranial volumes. This capability allows clinicians to extract neuroimaging biomarkers that improve decision-making in both clinical studies and routine practice, particularly in the context of multiple sclerosis, stroke, and neurodegenerative diseases. By integrating seamlessly into the workflows of imaging contract research organizations, neuroradiologists, and neurologists, Pixyl aims to facilitate data-driven and value-based patient care, ensuring that vital information is accessible to healthcare providers when it is most needed.

UroMems is a company dedicated to addressing specific clinical needs related to patient care, particularly in the area of urology. It develops implantable medical devices aimed at enhancing existing surgical treatments, thereby improving patient outcomes and reducing side effects. By focusing on innovative solutions, UroMems seeks to ensure that more patients can access effective treatments quickly, ultimately aiming to enhance their quality of life. The company is committed to the design, development, and commercialization of these active implantable devices, which reflect a deep understanding of the challenges faced by patients.